Multidisciplinary Head and Neck Cancers Symposium | Conference

Tisotumab Vedotin Yields Promising Preliminary Activity in SCCHN
March 02, 2022

Patients with squamous cell carcinoma of the head and neck who had progressive disease following treatment with platinum-based chemotherapy and a checkpoint inhibitor experienced promising safety and preliminary efficacy following treatment with tisotumab vedotin.

Tumor-Focused Stereotactic Radiotherapy May be Efficacious in Early Stage Glottic Larynx Carcinoma
February 28, 2022

Patients with early stage glottic larynx carcinoma benefitted from treatment with tumor-focused stereotactic radiotherapy.

RP1/Nivolumab Yields Promising Antitumor Activity in Non-Melanoma Skin Cancer
February 26, 2022

Patients with non-melanoma skin cancer achieved promising antitumor activity following treatment with RP1 and nivolumab.

Circulating TTMV HPV Tumor DNA May Detect Recurrence of HPV-Driven Oropharyngeal Cancers
February 25, 2022

Research presented at the 2022 Multidisciplinary Head and Neck Cancers Symposium highlighted the potential to detect oropharyngeal cancer recurrence using circulating tumor tissue modified viral–human papillomavirus DNA.

Radiotherapy De-Escalation Improves Toxicity in p16+ Oropharyngeal Squamous Cell Carcinoma
February 25, 2022

A presentation from the 2022 ASTRO Multidisciplinary Head and Neck Cancers Symposium showed a de-escalated radiotherapy dose to 54 Gy vs 70 Gy led to better measures of toxicity in those with p16+ oropharyngeal squamous cell carcinoma.

DART Meets Noninferiority PFS Benchmark in HPV-Related OPSCC
February 25, 2022

In a pre-planned pooled analysis of data from the MC1273 and MC1675 trials presented at the 2022 ASTRO Multidisciplinary Head and Neck Cancers Symposium, de-escalated adjuvant radiation therapy met criteria for efficacy in human papillomavirus–related oropharyngeal squamous cell carcinoma.